Aperiomics Launches First Commercial Services
Friday, November 14, 2014
Aperiomics, bearing a name based on the Latin word aperio (which means to reveal), introduced its breakthrough Absolute-NGS™ Pathogen Detection Platform to the Association for Molecular Pathology at the AMP 2014 Annual Meeting held November 12-15 near Washington, D.C.
The package includes three next-generation sequencing services to provide laboratories, public health care, and businesses the tools they need to make rapid and exact identification of known and unknown pathogens, whether bacteria, virus, fungus, or parasite. Their unique process addresses the biggest challenge in applying next-generation sequencing to real-world analysis – making sense of the massive amount of data spawned by next generation sequencing.
According to Jeff Gallagher, CEO of Virginia Bio, “Much of the promise of the future of health care and biomedical research depends on innovative use of data analytics. Done right, this will yield speed, power and insights well beyond forerunner products and services based solely in biology and chemistry. It will open up unimaginable new opportunities to create value for patients worldwide. Aperiomics is a case in point.”
From a single test, Aperiomics’ innovative technology can simultaneously test for all pathogens using an unbiased sequencing and genomic analysis approach. The range of samples can include tissue, blood, plant, animal, or environmental. With their novel combination of genomics and informatics, the company capitalizes on high-throughput next-generation sequencing and advanced Bayesian statistics to produce faster and better results than culture-based methods and even more accurate results than other molecular-based approaches.
Aperiomics CEO Crystal Icenhour, PhD, explains the importance of these services. “The majority of pathogens are currently never identified. Thus, the advantages of accurate determination can be measured with improvements in human health, significant cost savings, and reduced risks to public health.”
The technology behind Aperiomics’ services is the result of collaboration by three of the firm’s co-founders. The company’s President, Keith A. Crandall, PhD, is Director of the Computational Biology Institute at George Washington University; Chief Technology Officer W. Evan Johnson, PhD, is an assistant professor of Medicine, Biostatistics, and Bioinformatics at the Boston University School of Medicine; Chief Science Officer Eduardo Castro-Nallar, PhD received his degree in Biological Sciences from George Washington University.